Corporation - Media & Press - Press Releases
Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test
Source: Arrayit Corporation on April 4, 2012 at 5:30 AM EST
SUNNYVALE, Calif., April 4, 2012 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB: ARYC) and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx®. In this study, OvaDx® recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer.
Since July of 2009, AD has operated as an independent subsidiary of Arrayit Corporation and holds all the intellectual property, licenses and development agreement assets related to the pre-symptomatic ovarian cancer diagnostic test known as OvaDx®. On December 14th, 2011, Arrayit Corporation announced the spin-off of AD and the distribution of its 78.18% interest in AD as a stock dividend to ARYC shareholders. The record date, dividend distribution date and further details will be announced shortly.
"We continue to make additional enhancements subsequent to this pilot study that indicate improvements in the sensitivity number approaching 90%. We are working to make this diagnostic test superior to any existing test. Requiring only a finger stick of blood, this will also be the easiest test to administer," says Dr. Mark Schena, President and Chief Scientific Officer of Arrayit Corporation.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.
About Arrayit Diagnostics
Arrayit Diagnostics, headquartered in Redmond, Oregon, is leading the research and approval process of the pre-symptomatic ovarian cancer test, OvaDx®, based on molecular diagnostic technology.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-KA for the fiscal year ended December 31, 2011 and Form 10-Q for the quarter ended September 30, 2011.
Copyright 1993-2014 Arrayit Corporation. All rights reserved.